1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 30,400 | 31,450 | 30.04. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 25.04. | Spyre Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 19.04. | Spyre Therapeutics files to sell 33.36M shares of common stock for holders | 1 | Seeking Alpha | ||
| 18.03. | Spyre Therapeutics Privately Places $180 Mln Of Shares; Stock Up In Pre-Market | 2 | RTTNews | ||
| 18.03. | Spyre Therapeutics climbs 5%, prices $180M private financing | 2 | Seeking Alpha | ||
| 18.03. | Spyre Therapeutics secures $180 million in PIPE deal | 1 | Investing.com | ||
| 18.03. | Spyre Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.03. | Spyre Therapeutics, Inc. - S-1/A, General form for registration of securities | 1 | SEC Filings | ||
| 08.03. | XFRA NEW INSTRUMENTS AVAILABLE ON XETRA - 08.03.2024 | 296 | Xetra Newsboard | The following instruments on XETRA do have their first trading 08.03.2024 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 08.03.2024
Aktien
1 US12738K1097 Cadeler A/S ADR
2 US3793786076... ► Artikel lesen | |
| 04.03. | Spyre Therapeutics Inc reports results for the quarter ended in December - Earnings Summary | 2 | Reuters | ||
| 01.03. | Spyre Therapeutics, Inc.: Spyre Therapeutics Announces Grants of Inducement Awards | 299 | PR Newswire | WALTHAM, Mass., March 1, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a development-stage biotechnology company advancing best-in-class antibody engineering... ► Artikel lesen | |
| 01.03. | Spyre Therapeutics, Inc. - S-1/A, General form for registration of securities | 1 | SEC Filings | ||
| 01.03. | Spyre Therapeutics, Inc. - 10-K/A, Annual Report | 1 | SEC Filings | ||
| 01.03. | Spyre Therapeutics GAAP EPS of -$4.05 | 1 | Seeking Alpha | ||
| 29.02. | Spyre Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 29.02. | Spyre Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 29.02. | Spyre Therapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 29.02. | Spyre Therapeutics, Inc.: Spyre Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update | 161 | PR Newswire | Announced corporate name change to Spyre Therapeutics; appointment of Cameron Turtle, DPhil, as Chief Executive Officer; and began trading on Nasdaq under the symbol "SYRE"
SPY001, an anti-a4ß7 antibody... ► Artikel lesen | |
| 05.02. | Spyre Therapeutics appoints Mark C. Mckenna to its Board | 1 | Seeking Alpha | ||
| 05.02. | Spyre Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 05.02. | Spyre Therapeutics, Inc.: Spyre Therapeutics Appoints Accomplished Biopharma and IBD Leader Mark C. McKenna, Former Chairman, President, and CEO of Prometheus Biosciences, to its Board of Directors | 157 | PR Newswire | WALTHAM, Mass., Feb. 5, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a development-stage biotechnology company advancing best-in-class antibody engineering... ► Artikel lesen |
Seite:
1 2 3 Weiter >>
42 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 9,740 | +1,19 % | Kein Ausblick: Evotec crasht nach Zahlen um ein Drittel auf Tiefststand seit 2017 | © Foto: Breuel-Bild/dpaEvotec hat mit den Zahlen für das abgelaufene Jahr die Erwartungen enttäuscht und zudem noch keinen Ausblick geliefert. Was ist da los?Der Hamburger Wirkstoffforscher und -entwickler... ► Artikel lesen | |
| VALNEVA | 3,400 | 0,00 % | Absturz bei Valneva! | Nichts zu feiern gibt es heute für Valneva-Aktionäre. Das Kurstableau weist nämlich ein Minus von rund vier Prozent aus. Mittlerweile kosten die Papiere nur noch 7,24 USD. Ist das nur ein kurzzeitiger... ► Artikel lesen | |
| CORE ONE LABS | 0,158 | +4,30 % | Sondermeldung: Gar mehrere hundert Prozent bis zur Bescherung? Wo die Community jetzt auf eine Jahresendrallye spekuliert… | ||
| MAINZ BIOMED | 0,829 | +1,10 % | EQS-News: Mainz BioMed N.V.: Positive Topline-Ergebnisse einer gepoolten Studie zur Evaluierung neuartiger mRNA-Biomarker und des firmeneigenen KI-Algorithmus zur Integration in die klinische FDA-Zulassungsstudie | Emittent / Herausgeber: Mainz BioMed N.V.
/ Schlagwort(e): Studienergebnisse
Mainz Biomed: Positive Topline-Ergebnisse einer gepoolten Studie zur Evaluierung neuartiger mRNA-Biomarker... ► Artikel lesen | |
| TREVENA | 0,382 | +2,96 % | Trevena, Inc.: Trevena Awarded OLINVYK Agreement with Premier, Inc. | CHESTERBROOK, Pa., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Trevena Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with... ► Artikel lesen | |
| BLUEBIRD BIO | 0,839 | -0,05 % | bluebird bio receives non-compliance notice from Nasdaq | ||
| GALAPAGOS NV | 26,660 | +0,23 % | Galapagos NV: Galapagos' shareholders adopt all resolutions proposed by the Board of Directors at the Annual and Extraordinary Shareholders Meetings 2024 | Mechelen, Belgium; 30 April 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announces that all resolutions proposed at the company's Annual and Extraordinary Shareholders' Meetings (AGM... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 2,920 | +0,69 % | Cellectar Biosciences Reports Financial Results for Year Ended 2023 and Provides a Corporate Update | FLORHAM PARK, N.J., March 27, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization... ► Artikel lesen | |
| FRESH TRACKS THERAPEUTICS | 0,730 | 0,00 % | Fresh Tracks Therapeutics, Inc.: Fresh Tracks Therapeutics Urges Stockholders to Vote at the Upcoming Special Meeting on February 15th | Stockholders of record on January 11, 2024 who have not yet voted are encouraged to do so by 11:59 p.m. Eastern Time on February 14, 2024 BOULDER, Colo., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Fresh Tracks... ► Artikel lesen | |
| SENSEI BIOTHERAPEUTICS | 0,926 | -1,70 % | Sensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual Meeting | ||
| COHERUS | 1,993 | +8,23 % | Coherus BioSciences, Inc.: Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting | ||
| CHIMERIX | 0,856 | +1,54 % | Chimerix Inc reports results for the quarter ended in March - Earnings Summary | ||
| AYALA PHARMACEUTICALS | 0,455 | -6,19 % | Ayala Pharmaceuticals, Inc. - 10-K/A, Annual Report | ||
| CYTOMX THERAPEUTICS | 1,476 | -3,66 % | What's Going On With CytomX Stock? | ||
| ARCA BIOPHARMA | 3,260 | -1,21 % | ARCA biopharma, Inc.: ARCA biopharma Announces First Quarter 2024 Financial Results and Provides Corporate Update | ARCA biopharma and Oruka Therapeutics announce Merger AgreementARCA biopharma appoints Thomas Keuer as President WESTMINSTER, Colo., April 25, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq:... ► Artikel lesen |
SPYRE THERAPEUTICS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +1,200 (+3,89 %) liegt der Kurs bei 32,050 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
